Business Wire

CYNORA Announces Availability of Industry’s First Device Test Kits for TADF Deep Green Emitters for Next-Generation OLED Displays

20.1.2021 09:00:00 EET | Business Wire | Press release

Share

Marking a new innovation trajectory for the OLED industry, CYNORA today announced that device test kits for its Thermally Activated Delayed Fluorescence (TADF)-based Deep Green emitter for next-generation OLED displays are now available to customers. The development is an industry-first milestone for TADF technology, and validates CYNORA’s roadmap commitment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006159/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

cyUltimateGreen™ - CYNORA's TADF Deep Green Emitter Device Test Kit (Photo: Dr. Harald Flügge, CYNORA)

Known as the cyUltimateGreen™, the product delivers efficiency of more than 20 percent, which meets current industry specifications of 150cd/A in top emission devices. It demonstrates lifetime of 400h LT95@15mA, and color point and spectra that match today’s DCI-P3 standard. In addition, the product shows compatibility with BT2020, a color standard that requires greater color purity than DCI-P3, and one that will significantly enlarge the color depth.

The milestone delivers a materials technology breakthrough that will help display manufacturers unleash the full efficiency potential of new-generation OLEDs and catalyze game-changing OLED products. It starts with TADF Deep Green and will soon include a TADF Deep Blue solution.

The cyUltimateGreen Emitter: A “Brightness” Booster for Next-Generation OLEDs

Within the OLED stack is the emissive layer. This is where the light is made. Within the layer are Red, Green and Blue pixels. By combining all three, the full color gamut is rendered in the display. The Green pixel influences brightness. It accounts for as much as 25 percent of the OLED stack costs.

CYNORA’s CEO, Adam Kablanian, commented: “We set out to innovate a differentiated new technology that would enable display leaders to leapfrog beyond legacy emitter solutions for next-generation OLEDs. We believed that TADF was the most promising approach. We knew that with the right blend of advanced technologies and chemistry expertise, the breakthrough was achievable. Our talented team has confirmed the commercial capability of the TADF emitter technology, which has the ability to offer customers substantial savings. The kits are now ready for customer testing and verification.”

GEM: CYNORA’s Materials Discovery Advantage

Behind the cyUltimateGreen product is CYNORA’s Generative Exploration Model (GEM). GEM is the materials discovery engine pioneered by CYNORA to identify with extreme precision the most relevant and useful molecules, and related combinations, from an infinite source of chemical molecules.

GEM combines two key elements: artificial intelligence (AI) and the brainpower of CYNORA’s chemists. While AI offers immense computational capabilities, there can be prediction errors and other uncertainties that diminish the output of useful data for specialized applications. GEM supercharges AI for OLED materials discovery by pairing its computing power with the materials expertise and OLED device knowledge of CYNORA’s chemists to identify molecules with high potential. From there, a scoring system predicts how closely the molecule conforms to must-have parameters, as well as its usefulness for the target purpose – in this case, high-efficiency emitter materials.

GEM strengthened CYNORA’s discovery and synthesis capabilities, and fast-tracked completion of the cyUltimateGreen product, said CTO, Dr. Jan Richter. “Given that the universe of chemical molecules is infinite, identifying the most relevant molecules is exceedingly tough,” he said. “While AI gives us a powerful discovery acceleration tool, our imperative isn’t just to find molecules that are a theoretical fit; they must also be chemically synthesizable. That’s where CYNORA’s chemistry expertise provides the value add.”

The expertise extends to CYNORA technologists’ deep knowledge of the full OLED device. This helped the company engineer the cyUltimateGreen to meet mass-production requirements, without requiring display leaders to make expensive alterations to their manufacturing lines. Essential details like matching evaporation temperatures to meet current device architectures, and aligning material parameters (like energy levels), were part of the calculations. To further reduce cost, integration factors were also considered, like how to manufacture the product within existing hardware and process frameworks without requiring extra evaporation chambers.

Richter added: “TADF technology is igniting a new innovation trajectory for OLED emitter materials. We’re excited to lead with our cyUltimateGreen product.”

For information on CYNORA GmbH, please visit www.cynora.com

cyUltimateGreen is a trademark of CYNORA GmbH

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Company Contact
Joanna Folberth; email: folberth@cynora.com

Agency Contact
Genuity Communications for CYNORA; email: cynora@genuitypr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye